Title:
ＰＡＣ１受容体作動薬（ＭＡＸＣＡＰ）及びその用途
Document Type and Number:
Japanese Patent JP7183164
Kind Code:
B2
Abstract:
In certain embodiments novel PAC1 receptor agonists are provided wherein the agonists comprise a targeting sequence that binds to the PAC1 receptor and said targeting sequence is attached to an amino acid sequence comprising a fragment of the maxadilan amino acid sequence, wherein the targeting sequence comprises a full-length 38 amino acid PACAP peptide or an N-terminus fragment thereof containing the amino acid sequence HSDGIF, wherein said targeting sequence optionally comprises an amino acid insertion between residues 11 and 12 of said PACAP peptide or fragment thereof; and the fragment of the maxadilan amino acid sequence comprises a fragment of the maxadilan sequence effective to activate PAC1 signaling.
More Like This:
Inventors:
Joseph Earl Pisegna
Patrizia M Germano
John Peeve
Patrizia M Germano
John Peeve
Application Number:
JP2019537254A
Publication Date:
December 05, 2022
Filing Date:
January 04, 2018
Export Citation:
Assignee:
The Regents of the University of California
International Classes:
A61K38/22; A61K47/56; A61K47/62; A61K47/64; A61K47/65; A61P1/04; A61P1/16; A61P3/00; A61P3/04; A61P3/10; A61P5/50; A61P7/04; A61P9/10; A61P9/12; A61P11/00; A61P11/06; A61P13/12; A61P15/08; A61P19/04; A61P19/08; A61P21/04; A61P25/00; A61P25/02; A61P25/18; A61P25/28; A61P27/02; A61P27/06; A61P29/00; A61P35/00; A61P35/04; A61P37/02; A61P37/06; A61P37/08; A61P39/02; A61P43/00; C07K14/435; C07K14/575; C07K19/00
Other References:
Vu, J. P. et al.,PACAP intraperitoneal treatment suppresses appetite and food intake via PAC1 receptor in mice by inhibiting ghrelin and increasing GLP-1 and leptin,American Journal of Physiology. Gastrointestinal and Liver Physiology,2015年,Vol.309, No.10,p.G816-G825,doi:10.1152/ajpgi.00190.2015
Moro, O. et al.,Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist,The Journal of Biological Chemistry,1999年,Vol.274, No.33,p.23103-23110,doi:10.1074/jbc.274.33.23103
Reddy, V. B. et al.,Functional analysis of recombinant mutants of maxadilan with a PAC1 receptor-expressing melanophore cell line,The Journal of Biological Chemistry,2006年,Vol.281, No.24,p.16197-16201,doi:10.1074/jbc.M509429200
Moro, O. et al.,Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist,The Journal of Biological Chemistry,1999年,Vol.274, No.33,p.23103-23110,doi:10.1074/jbc.274.33.23103
Reddy, V. B. et al.,Functional analysis of recombinant mutants of maxadilan with a PAC1 receptor-expressing melanophore cell line,The Journal of Biological Chemistry,2006年,Vol.281, No.24,p.16197-16201,doi:10.1074/jbc.M509429200
Attorney, Agent or Firm:
Murayama Yasuhiko
Shinya Mihiro
Tatsuhiko Abe
Shinya Mihiro
Tatsuhiko Abe